NCT00304551 - A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC) | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

June 30, 2010

Conditions

Liver CirrhosisChronic Hepatitis C

Interventions

DRUG

peginterferon alfa-2a 180μg

180μg（s.c.）/week for 48 weeks

DRUG

peginterferon alfa-2a 90μg

90μg(s.c.)/week for 48 weeks

DRUG

ribavirin

600, 800, or 1,000 mg X 2(p.o.)/day

Trial Locations (8)

Chugoku, Chugoku

Hokkaido Region, Hokkaido

Kanto Region, Kanto

Kinki Region, Kinki

Kyusyu Region, Kyusyu

Shikoku Region, Shikoku

Tohoku Region, Tōhoku

Tokai Region, Tōkai